[Event Report] Roundtable – Preparatory Meeting: The Management Structure and FY2019 Activities of AMR Alliance Japan (March 19, 2019)
date : 4/12/2019
Tags: AMR
Every year, Antimicrobial Resistance (AMR) kills approximately 700,000 people globally. In Japan, AMR has become a major challenge for many medical facilities, with cases of community-acquired drug-resistant infections on the rise nationally. To combat this issue, Japan enacted a National Action Plan on Antimicrobial Resistance in April 2016.
Sensing the growing concern about AMR domestically and abroad, HGPI has taken the initiative to host multiple expert meetings on this subject since 2016. Over the course of those expert meetings, it was suggested that the establishment of an independent platform for multi-stakeholder discussion on AMR was needed to encourage more impactful collaborations on the AMR policies.
To that end, in November 2018, HGPI joined together with eight Japanese medical societies involved with infectious disease medicine to establish AMR Alliance Japan, a multi-stakeholder, collaborative body that will work to improve public health by promoting AMR countermeasures.
During this preparatory meeting, representatives of participating academic societies and FY2018 project sponsors came together to discuss the management structure of AMR Alliance Japan and the actions to be carried out by the Alliance in FY2019.
Organizer: HGPI
Participants: AMR Alliance Japan academic society members and corporate stakeholders
Opening (explanatory introduction)
Matt McEnany (Manager, Health and Global Policy Institute)
Roundtable Discussion
Roundtable Speakers (alphabetical order by last name)
Yusuke Ariyoshi (Director, Healthcare Policy, Government Affairs Dept., Shionogi & Co., Ltd.)
Hiroshi Kiyota (President, Japanese Society of Chemotherapy / Professor, Department of Urology, The Jikei University Katsushika Medical Center)
Shinya Nagase (Director, Diagnostic Systems, BD Life Sciences, Nippon Becton Dickinson Company, Ltd.)
Ryoji Noritake (CEO, Board Member, Health and Global Policy Institute)
Masahiro Okuda (President, Japanese Society of Pharmaceutical Health Care and Sciences / Professor, Faculty of Medicine, Mie University Graduate School)
Akio Ozaki (Director, Public and Industry Policy, Health Policy, MSD K. K.)
Kazutoshi Shibuya (President, The Japanese Society for Medical Mycology / Professor, Department of Surgical Pathology, Toho University)
Yoshinobu Takakura (Vice President, Candidate for President, The Pharmaceutical Society of Japan, / Professor, Graduate School of Pharmaceutical Sciences, Kyoto University)
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Yasunori Tawaragi (Director, International Affairs, Japan Pharmaceutical Manufacturers Association)
Masaki Yoshida (President, Japanese Society for Infection Prevention and Control / Professor, Department of Infectious Disease and Infection Control, The Jikei University School of Medicine)
日本語
Top Research & Recommendations Posts
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Publication Report] Guidance on Patient and Public Involvement (PPI) in Health Policymaking: Necessary Initiatives and Good Examples from the Public and Government (March 31, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Research Report] Healthcare DX Project Research Report of Interviews ”Expectations for the Coming Era of Healthcare DX from People Living with Health Concerns” (June 10, 2024)
- [Policy Recommendations] Recommendation for the Basic Policy on Economic and Fiscal Management and Reform 2024 (June 11, 2024)
- [Policy Recommendations] Kidney Disease Control Promotion Project 2023 “Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration” Policy Recommendations, a Collection of Good Practices of Chronic Kidney Disease (CKD) and Control Measures in Local Governments (February 14, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Public Comment Submission] Web based consultations on NCDs and mental health by World Health Organization (June 25, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
Featured Posts
-
2024-06-21
[Event Report] HGPI Special Seminar – HGPI Celebrates its 20th Anniversary: Reflecting on HGPI’s Journey from the Past to the Future (January 16, 2024)
-
2024-06-25
[Public Comment Submission] Web based consultations on NCDs and mental health by World Health Organization (June 25, 2024)
-
2024-06-26
[Event Report] Global Expert Meeting “Innovation in Cancer Care in Developing Countries ~City Cancer Challenge Initiatives“ (June 20, 2024)
-
2024-06-26
[Registration Open] (Webinar) The 127th HGPI Seminar: Current Issues and Future Prospects in Establishing a Health System and Protecting Public Health Through Policy (July 18, 2024)
-
2024-07-01
[Registration Open] Meaningful Involvement Promotion Project Online Expert Meeting “Shaping the Future of Health Policy with People with Lived Experience and Citizens” (July 26, 2024)